Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ian Haydock
Astellas has joined the growing ranks of research-based pharma firms offloading their older products in Japan, amid rising pricing and generic pressures and an increasing desire to focus on innovation.
In another vote of confidence in one of its newer respiratory assets, AstraZeneca is extending to Asia its already broad rights to benralizumab, adding to a deal it already has with Kyowa Hakko Kirin for Japan.
A Japanese official provides reassurances at BIO Asia that the government intends to abide by drug pricing policies that support innovation, although the research-based pharma industry remains concerned that sweeping reforms now under discussion may hamper R&D and investment in the country.
Bristol-Myers Squibb expanded its collaboration with CytomX for $200m up front and up to $3.6bn in milestone fees. Also, Takeda spun out eight non-core molecules into a new joint venture and X-Chem executed two deals with Japanese partners, among other recent deals.
Lilly says it remains on track to enter the pharma industry top 10 in Japan by sales by 2020, driven by planned launches of a raft of new products and despite some major recent losses of exclusivity.
Against a background of ongoing discussions in Japan over the reform of the drug pricing and reimbursement system, Pfizer is calling for greater industry participation and recognition of the value of innovation.